Materials and reagents

Biological materials

1. C57BL/6J mice, male or female (strain number: 00664)

2. BD Pharmingen^TM purified rat anti-mouse CD16/CD32 (mouse BD Fc Block™) (BD Bioscience, catalog number: 553141)

Reagents

1. Puromycin dihydrochloride from Streptomyces alboniger (PMY) (Sigma-Aldrich, catalog number: P8833-100MG)

2. Cycloheximide (CHX) (EMD Millipore, catalog number: 239764, 100 mg)

3. Methanol (certified ACS) (Fisher Chemical, catalog number: A412-4)

4. Harringtonine (HAR) (Santa Cruz Biotech, catalog number: sc-204771A)

5. RPMI 1640 medium, GlutaMAX^TM supplement (Thermo Fisher Scientific, catalog number: 61870036)

6. DPBS, no calcium, no magnesium (Thermo Fisher Scientific, catalog number: 14190144)

7. Anti-puromycin Ab, produced from in-house-generated hybridoma (Developmental Studies Hybridoma Bank, catalog number: PMY-2A4)

8. ACK lysing buffer (Lonza, catalog number: A1049201)

9. Trypan Blue solution, 0.4% (Thermo Fisher Scientific, catalog number: 15250061)

10. Fujifilm Wako chemicals USA digitonin 1 g (Fisher Scientific, catalog number: NC0141730)

11. Paraformaldehyde, 16% w/v aq. soln., methanol free (Thermo Fisher Scientific, catalog number: 043368.9M)

12. Fluorescent Protein Labeling kits (Thermo Fisher Scientific, catalog number: A10235)

13. Ethidium monoazide bromide (EMA) (Thermo Fisher Scientific, catalog number: E1374)

14. Bovine serum albumin (BSA) (Millipore Sigma, catalog number: A7888-10G)

15. Sodium azide (Millipore Sigma, catalog number: 71290)

16. Ethyl alcohol, pure (Millipore Sigma, catalog number: 459836-100ML)

17. Fetal bovine serum (FBS) (Atlanta Biologicals, catalog number: S10350)

Solutions

1. RPMI with 7.5% fetal bovine serum (see Recipes)

2. Puromycin (PMY), cycloheximide (CHX), and harringtonine (HAR) solution for IV injections (1 mL) (see Recipes)

3. Stock CHX solution (see Recipes)

4. Stock HAR solution (see Recipes)

5. Stock PMY solution (see Recipes)

6. HAR/PMY/CHX solution for intravenous injection (see Recipes)

7. HAR solution for intravenous injection (see Recipes)

8. Fluorescence-activated cell sorting (FACS) buffer (see Recipes)

9. Stock EMA solution (see Recipes)

10. Stock digitonin solution (see Recipes)

11. Fixation and permeabilization buffer (see Recipes)

Recipes

1. RPMI 1640 with 7.5% FBS

500 mL of RPMI 1640 with GlutaMAX

37.5 mL of FBS

Store at 4 °C.

2. Puromycin (PMY), cycloheximide (CHX), and harringtonine (HAR) solution for IV injections (1 mL)

1 mg of PMY, 100 μg of HAR, and 0.34 mg of CHX per mouse; 100 μL per mouse; make fresh from stocks.

20 μL of HAR stock solution

200 μL of PMY stock solution

170 μL of CHX stock solution

610 μL of PBS

Warm to 37 °C before use to allow PMY to fully solubilize, then keep at room temperature for up to 5 h.

3. Harringtonine (HAR) solution for IV infections (1 mL)

100 μg of HAR per mouse, 100 μL per mouse, make fresh from stocks.

20 μL of HAR stock solution

980 μL of PBS

Once made, use immediately. Can remain at room temperature for ~5 h.

4. CHX stock solution in 50% ethanol (20 mg/mL)

100 mg of CHX

5 mL of 50% ethanol, 50% water

Aliquot and store at -20 °C.

5. PMY stock solution in PBS (50 mg/mL)

100 mg of puromycin (PMY)

2 mL of PBS

Warm to 37 °C to solubilize, aliquot (we usually use 1 mL), and store at -20 °C.

6. Harringtonine (HAR) stock solution in methanol (50 mg/mL)

10 mg of HAR

200 μL of methanol

Aliquot and store at -20 °C.

7. 1% digitonin stock solution in DMSO

1 g of digitonin

100 mL of DMSO

Aliquot and store at -20 °C.

8. Fixation/permeabilization buffer (1% paraformaldehyde, 0.0075% digitonin)

9.3 mL of PBS

625 μL of 16% paraformaldehyde

75 μL of 1% digitonin

Make fresh and keep on ice.

9. FACS buffer (0.2% sodium azide, 1 mg/mL bovine serum albumin)

1 g of sodium azide

500 mg of BSA

500 mL of PBS

Store at 4 °C.

10. EMA stock solution (5 mg/mL)

5 mg of EMA

1 mL of DMSO

Aliquot and store at -20 °C.

11.Ethidium monoazide solution for staining (10 μg/mL)

20 μL of EMA stock solution

10 mL of PBS

Make fresh and keep on ice.

Laboratory supplies

1. Falcon^TM 15 mL conical polypropylene centrifuge tubes (Fisher Scientific, catalog number: 14-959-49B)

2. Corning^® Primaria ^TM 60 mm × 15 mm standard cell culture dish (Corning, catalog number: 353802)

3. Microscope slides, glass, 25 × 75 mm, 90° ground edges, frosted, 1 end, both sides (Globe Scientific, catalog number: 1308)

4. Falcon^® 70 μm cell strainer, white, sterile, individually packaged, 50 per case (Fisher Scientific, catalog number: 22-363-548)

5. Cellometer SD025 slides, box of 75 slides (Revvity, catalog number: CHT4-SD025-002)

6. Corning^® 96-well clear round bottom TC-treated microplate (Corning, product number: 3799)

7. BD Eclipse^TM needle 27 G × 1/2 in. with detachable 1 mL BD Luer-Lok^TM syringe (BD Biosciences, GTIN number: 00382903057894)

Equipment

1. Cellometer X2 fluorescent viability counter (Nexcelom, catalog number: CMT-X2-S150)

2. Tailveiner restrainer for mice (Braintree Scientific, Inc., SKU: TV-150)

3. Infrared heating and drying lamp, table model (Walter Stern, VWR, Avantor, catalog number: 36547-009)

4. Fisherbrand^TM accuSpin Max 1.6 L benchtop centrifuge (Fisher Scientific, catalog number: 75-883-78)

5. LSR Fortessa X-20 (BD Bioscience, catalog number: 50165)

Software and datasets

1. Microsoft Excel for Mac, version 16.85

2. GraphPad Prism 10 for MacOS

3. FlowJo 10.10.0 for Mac OS X

Procedure

A. Intravenous injections of reagents necessary for in vivo RiboPuroMycylation (RPM)

Note 1: All in vivo procedures require approval by your institutional Animal Care and Use Committee (ACUC).

Note 2: The in vivo RPM procedure has been successfully performed on lymph nodes, spleens, and thymi from mice, although a similar procedure has been performed in vitro on other organs such as fetal liver [10].

Note 3: For in vivo RPM and RTA procedures, we have used female and male mice aged 1.5–18 months. Mice were housed on a 12 h light/dark cycle with ad libitum access to normal mouse chow and water. The procedure was developed using C57BL/6J (B6) mice, and we have performed it using other mice on the B6 and FVB/N background. We expect this protocol will work similarly in other mouse strains and animal models, with adjustments to drug dosage.

1. For the in vivo RPM assay, prepare a solution of 10 mg/mL PMY, 1 mg/mL HAR, and 3.4 mg/mL CHX in PBS and warm in a water bath to 37 °C to allow PMY to completely solubilize (see Recipes). Prepare approximately 20% extra of this solution, as fluid loss during injections will occur.

2. Prepare a solution of 1 mg/mL of HAR in PBS (see Recipes). Prepare approximately 20% extra of this solution, as fluid loss during injections will occur.

3. Warm mice for 5–10 min using an ACUC-approved heat lamp to dilate tail veins. Mice are considered sufficiently warm for injections when their activity within the cage is increased.

4. Restrain warmed mice in a mouse holder and intravenously inject the tail vein, using a 27G × ½ needle attached to a 1 mL syringe, with 100 μL of the HAR/CHX/PMY solution, waiting 5 min for the maximum signal. To determine the background RPM signal not related to active protein synthesis, inject mice with 100 μL of the HAR solution, wait 15 min for ribosomes to finish translating mRNAs, and then inject 100 μL of the HAR/CHX/PMY solution and wait 5 min. A third control is necessary, injecting vehicle without PMY to control for non-specific staining of the anti-PMY mAb.

5. After the indicated times, sacrifice mice by cervical dislocation and harvest organs of interest into 15 mL conical centrifuge tubes containing 3 mL of RPMI supplemented with 7.5% FBS on ice.

Figure 1. Depiction of the in vivo RiboPuroMycylation (RPM)-ribosome transit assay (RTA). In this example, CFSE-labeled OT-1 T cells (CFSE tracks cell division) are adoptively transferred into congenic mice (to allow tracking of donor cells in recipient mice), followed by infection with vaccinia virus expressing the SIINFEKL peptide (Kb-SIINFEKL activates OT-1 T cells). RPM-RTA is performed by intravenous injection of harringtonine (HAR) for different amounts of time followed by HAR, cycloheximide (to prevent leakiness from HAR inhibition alone), and puromycin. Spleens are harvested for RPM analysis on both endogenous and transferred T cells. Schematic designed with BioRender.

B. Intravenous injections of reagents necessary for in vivo RPM ribosome transit analysis (RTA)

Note: The timing of intravenous injections is critical. It is strongly suggested that this procedure be done by a two-person team: one person using a timer to record the time of injections and the other to perform the injections.

1. For in vivo RPM RTA (depiction of an experimental setup in Figure 1), prepare a solution of 10 mg/mL PMY, 1 mg/mL HAR, and 3.4 mg/mL CHX and warm in a water bath to 37 °C to allow PMY to completely solubilize (see Recipes). Prepare approximately 20% extra of this solution, as fluid loss during injections will occur.

2. Prepare a solution of 1 mg/mL HAR (see Recipes). Prepare approximately 20% extra of this solution, as fluid loss during injections will occur.

3. Warm mice for 5–10 min using an ACUC-approved heat lamp to dilate tail veins. Mice are considered sufficiently warm for injections when their activity within the cage is increased.

4. Restrain warmed mice in a mouse holder, intravenously inject the tail vein using a 27G × ½ needle attached to a 1 mL syringe with 100 μL of the HAR/CHX/PMY solution, and wait 5 min for maximum signal. To determine ribosome transit times, inject 100 μL of HAR and wait for 30 s, 1 min, 2 min, 4 min, or 10 min before injecting with 100 μL of the HAR/CHX/PMY solution. As above, a no-PMY control is needed.

5. After the indicated times, sacrifice mice by cervical dislocation and harvest organs of interest into 15 mL conical centrifuge tubes containing 3 mL of RPMI supplemented with 7.5% FBS on ice.

C. Preparation of single-cell samples for flow cytometry

Note 1: All steps below are performed at 4 °C with ice-cold solutions.

Note 2: We have stained anywhere from 1 to 6 million cells per well in a 96-well plate, with adjustments to antibody concentrations for surface and intracellular antigens.

1. Crush organs (we have used spleens, thymi, or lymph nodes) in 3 mL of RPMI between two frosted microscope slides in a 60 mm × 15 mm standard cell culture dish. Filter resultant single-cell suspensions through a 70 μm mesh screen back into a standard polyethylene 15 mL centrifuge tube.

2. Lyse red blood cells present in tissue samples by adding 6 mL of ACK lysing buffer directly to the single cell suspensions and mix by quickly rotating the tubes.

3. Centrifuge filtered single-cell suspensions at 350× g for 4 min at 4 °C and pour off supernatants. Disrupt cell pellets by tapping the bottom of the 15 mL conical centrifuge tubes quickly 3–4 times. Resuspend cells in 3 mL of cold RPMI supplemented with 7.5% FBS. Centrifuge at 350× g for 4 min at 4 °C, pour off supernatants, disrupt cell pellet, and add 3 mL of cold RPMI supplemented with 7.5% FBS. Refilter cell suspensions again through a 70 μm mesh screen.

4. Count resuspended cells with a Nexcelom Cellometer Vision using Trypan Blue (1:1 dilution) for live/dead cell discrimination as per the manufacturer’s instructions. After counting, centrifuge the cell suspensions in 15 mL conical centrifuge tubes at 350× g for 4 min at 4 °C, pour off supernatants, disrupt cell pellets, and resuspend cells in cold RPMI supplemented with 7.5% FBS at 10 million cells per milliliter. Add 200 μL (1–6 million cells per well can be plated; here, 2 million cells per well are plated) of the cell suspensions from each sample to a well of a 96-well polystyrene U-bottom plate.

D. Surface and intracellular stains for flow cytometry analysis

Note 1: Stains for flow cytometry are all performed on ice.

Note 2: Anti-puromycin Ab should be conjugated with the required fluorochrome ahead of time with a Life Technologies Protein Labeling kit as per the manufacturer’s instructions.

Note 3: The fluorescence signal from the fluorochrome-conjugated anti-puromycin Ab will dim over time. It is recommended that you only use the conjugated anti-PMY Ab for six months.

1. For single-color controls (SCC) and fluorescence-minus-one (FMO) controls, prepare a mixture of equal numbers of cells from each sample for each organ type isolated (all splenocytes in one mixture, all cells from thymi in a separate mixture). This mixture is made for appropriate flow cytometer setup and downstream analysis. New SCCs and FMOs should be prepared for each experiment. Settings on the flow cytometer may be reused, depending on the experience of the experimenter.

2. Mix Abs at proper dilutions in FACS buffer for SCCs, FMOs, and the full Ab mix to allow for 100 μL per sample in the 96-well plate. Centrifuge cells in the 96-well plate at 350× g for 4 min at 4 °C. Before dumping the supernatant [with one (!) quick smooth wrist flick into a biohazard bucket], check that solid cell pellets have formed at the bottom of the 96-well plate.

3. Resuspend cells in 200 μL of PBS using a 12-well multichannel pipette. Centrifuge the plate as above. Dump the supernatant and resuspend the appropriate FMOs, SCCs, and samples in 100 μL of a 10 μg/mL solution of EMA in PBS for flow-based live/dead cell discrimination (see Recipes). Place the plate in the dark on ice for 10 min. Next, expose the uncovered plate close to a fluorescent light with the lid off for an additional 10 min on ice. While exposure to a commercial fluorescent light is suitable for crosslinking EMA to DNA, a wavelength of 465–475 nm has been described to work in the PMA-Lite^TM 2.0 LED Photolysis Device (Biotium, catalog number: E90006). Add 100 μL of PBS to each well, pipette up and down to mix, and centrifuge as above. After washing with 200 μL of PBS twice, perform surface staining.

4. Resuspend cells in 100 μL of FACS buffer with the 2.42G monoclonal antibody (Ab) to block Fc receptors (dilution as per manufacturer’s instructions) on ice for 10 min. Add 100 μL of the appropriate single Abs for SCCs, Ab mixes for FMOs, or full Ab mix for full stains, to cell surface antigens at appropriate dilutions for 30 min at 4 °C (a common Ab panel we use and the associated dilutions are listed in Table 1). Centrifuge as above and wash twice in 200 μL of PBS.

Table 1. Example flow cytometry panel

5. Next, simultaneously fix and permeabilize cells in 100 μL of freshly made fixation/permeabilization buffer (fix/perm) (1% PFA, 0.0075% digitonin in PBS, see Recipes) for 20 min at 4 °C. Add 100 μL of PBS, centrifuge as above, and wash twice with PBS.

6. Stain for PMY after the fix/perm step using a 1:100 dilution of the conjugated anti-PMY Ab for 1 h (it could be overnight if more convenient). Add 100 μL of PBS, pipette up and down 6–8 times, and centrifuge the plate as above. Wash twice with 200 μL of PBS, resuspend cell pellets in FACS buffer, and analyze samples (samples should remain on ice during the run) with a flow cytometer. Samples may be stored in a dark refrigerator for up to a week prior to running on a flow cytometer. We use a BD LSRII or BD LSR Fortessa X-20 to run samples, but any flow cytometer with the appropriate lasers and filter sets may be used.

Data analysis

1. Analyze resulting data using FlowJo, Microsoft Excel, and GraphPad Prism software. For our analysis, we gated OT-1 CD8⁺ T cells by gating on singlets by FSCa and FSCw, lymphocytes by SSCa and FSCa, live cells by EMA-, T cells by CD3⁺CD19-, CD8⁺ T cells by CD8⁺CD4-, adoptively transferred cells by CD45.1⁺CD4-, and OT1 T cells by Vb5⁺CD45.2-, as shown in Figure 2a. For RPM values, we took the population of interest, in this case adoptively transferred OT-1 CD8⁺ T cells, and determined the mean fluorescence intensity (MFI) of PMY staining in mice treated with different inhibitors of either the CFSE⁺ population in uninfected mice or the CFSE- population in day 3 VACV-SIINFEKL-infected mice. We chose an OT1 T-cell experiment with CFSE labeling (CFSE tracks cell division, CFSE hi are undivided, CFSE low are divided) to distinguish the difference in protein synthesis in actively dividing vs. resting (non-dividing) T cells.

2. For the in vivo RPM assay, subtract the no-PMY MFI in your population of interest (OT1 T cells here) from the HAR/CHX/PMY-treated PMY MFI (maximum signal). Next, subtract the no-PMY PMY MFI signal from the 15-min HAR-treated and then the HAR/CHX/PMY PMY signal.

Note: Typically, only two no-PMY-treated mice are required for each manipulation, and the average of the RPM MFIs of the no-PMY-treated mice are taken, as the MFI for each no-PMY mouse should be very similar.

3. Next, subtract the no-PMY-subtracted 15-min HAR-treated and then HAR/CHX/PMY-treated PMY signal from the no-PMY-subtracted HAR/CHX/PMY PMY signal. This will be the relative number of ribosomes in the cell population analyzed (RPM value). If the 15-min HAR-treated and then HAR/CHX/PMY-treated runoff RPM signal is consistently higher than the no-PMY RPM signal, this could be an example of stalled translation, as we have seen in cultured un-activated lymphocytes in vitro [8] and has also been described in neurons [7].

4. For the in vivo RTA assays, the initial analysis is the same, but as the analysis is for different times after runoff, the resultant values are plotted in GraphPad Prism against the time of each individual HAR treatment, and a one-phase decay analysis is performed on the resultant graph. An example of graphed data normalized to the maximum signal from three different experiments is shown in Figure 2b. In this example, we examine translation elongation rates in both non-activated polyclonal T cells and activated OT1 transgenic T cells.

Figure 2. Example gating strategy and RiboPuroMycylation ribosome transit analysis data A. On the left: Gating on OT-1 T CD8⁺ T cells. Singlets by FSCa and FSCw, lymphocytes by SSCa and FSCa, live cells by EMA-, CD3⁺CD19-, CD8⁺ T cells by CD8⁺CD4-, adoptively transferred cells by CD45.1⁺CD4-, and OT1 T cells by Vb5⁺CD45.2-. On the right: RiboPuroMycylation (RPM) staining of divided (CFSE-, infected mice) or undivided (CFSE⁺, uninfected mice) OT-1 CD8⁺ T cells, with an example of harringtonine runoff after different harringtonine treatment times in CFSE- cells. B. RPM-Ribosome Transit Analysis (RTA) of adoptively transferred activated OT-1 T cells or un-activated (resting) host CD8⁺ T cells in mice infected for 2 or 3 days with VACV-SIINFEKL. Three to four independent experiments combined. Normalized by setting the corrected maximum RPM signal (no runoff) to 100.

Validation of protocol

This protocol or parts of it has been used and validated in the following research article:

1. Seedhom et al. [8]. Paradoxical imbalance between activated lymphocyte protein synthesis capacity and rapid division rate. eLife.

General notes and troubleshooting

1. While extensively validated in lymphocytes and CFSE-labeled lymphocytes from the spleen, thymus, and lymph nodes in two different strains of mice (C57BL/6J and FVB/N) as well as RAG1ko OT1 TCR transgenic mice, this protocol relies on intravenous delivery of protein synthesis modifiers and detection reagents that work similarly in many mammals, so we expect it to be applicable to many other model organisms and most cells in tissue types that are well-vascularized that can be processed to single cells.

2. The reagents puromycin and digitonin vary somewhat from lot to lot and especially from the company purchased. We suggest piloting these reagents ahead of time in comparison experiments, and then ordering and freezing these reagents in bulk for future studies.

Acknowledgments

We thank Alexandre David for developing the original in vitro RPM protocol and Jaroslav Holly for helping with experiments.

Competing interests

The authors declare no conflict of interest.

Ethical considerations

All animal studies were approved by and performed in accordance with the Animal Care and Use Committee of the National Institute of Allergy and Infectious Diseases under protocol LVD-5E.

References

1. Hosios, A. M., Hecht, V. C., Danai, L. V., Johnson, M. O., Rathmell, J. C., Steinhauser, M. L., Manalis, S. R. and Vander Heiden, M. G. (2016). Amino Acids Rather than Glucose Account for the Majority of Cell Mass in Proliferating Mammalian Cells. Dev Cell. 36(5): 540–549. https://doi.org/10.1016/j.devcel.2016.02.012.
2. Mourant, J. R., Short, K. W., Carpenter, S., Kunapareddy, N., Coburn, L., Powers, T. M. and Freyer, J. P. (2005). Biochemical differences in tumorigenic and nontumorigenic cells measured by Raman and infrared spectroscopy. J Biomed Opt. 10(3): 031106. https://doi.org/10.1117/1.1928050.
3. Nathans, D. (1964). Puromycin Inhibition of Protein Synthesis: Incorporation of Puromycin into Peptide Chains. Proc Natl Acad Sci USA. 51(4): 585–592. https://doi.org/10.1073/pnas.51.4.585.
4. Aviner, R., Geiger, T. and Elroy-Stein, O. (2013). Novel proteomic approach (PUNCH-P) reveals cell cycle-specific fluctuations in mRNA translation. Genes Dev. 27(16): 1834–1844. https://doi.org/10.1101/gad.219105.113.
5. David, A., Dolan, B. P., Hickman, H. D., Knowlton, J. J., Clavarino, G., Pierre, P., Bennink, J. R. and Yewdell, J. W. (2012). Nuclear translation visualized by ribosome-bound nascent chain puromycylation. J Cell Biol. 197(1): 45–57. https://doi.org/10.1083/jcb.201112145.
6. Seedhom, M. O., Hickman, H. D., Wei, J., David, A. and Yewdell, J. W. (2016). Protein Translation Activity: A New Measure of Host Immune Cell Activation. J Immun. 197(4): 1498–1506. https://doi.org/10.4049/jimmunol.1600088.
7. Graber, T. E., Hebert-Seropian, S., Khoutorsky, A., David, A., Yewdell, J. W., Lacaille, J. C. and Sossin, W. S. (2013). Reactivation of stalled polyribosomes in synaptic plasticity. Proc Natl Acad Sci USA. 110(40): 16205–16210. https://doi.org/10.1073/pnas.1307747110.
8. Seedhom, M. O., Dersh, D., Holly, J., Pavon-Eternod, M., Wei, J., Angel, M., Shores, L., David, A., Santos, J., Hickman, H., et al. (2024). Paradoxical imbalance between activated lymphocyte protein synthesis capacity and rapid division rate. eLife. 12. https://doi.org/10.7554/eLife.89015.
9. Aviner, R. (2020). The science of puromycin: From studies of ribosome function to applications in biotechnology. Comput Struct Biotechnol J. 18: 1074–1083. https://doi.org/10.1016/j.csbj.2020.04.014.
10. Arguello, R. J., Reverendo, M., Mendes, A., Camosseto, V., Torres, A. G., Ribas de Pouplana, L., van de Pavert, S. A., Gatti, E. and Pierre, P. (2018). SunRiSE - measuring translation elongation at single-cell resolution by means of flow cytometry. J Cell Sci. 131(10). https://doi.org/10.1242/jcs.214346.